Penile TPF

Phase II trial of docetaxel, cisplatin and 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis.

Disease site: Urological cancers

Treatment Modality: Chemotherapy

Status: Closed

Trial details

The primary objective of the trial is to determine the activity of combination docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in cancer of the penis.

A total of 29 patients, with histologically-proven squamous cell carcinoma of the penis, were recruited. Patients entered onto the trial received three courses of TPF chemotherapy. 

The primary endpoint is overall response rate (complete remission rate + partial remission rate). The secondary endpoints are to determine the proportion of patients with inoperable locoregional disease rendered operable following TPF, to evaluate safety and tolerability, and to assess progression-free and overall survival.

Chief Investigator: Dr Amit Bahl, Bristol Haematology and Oncology Centre.

Co-Chief Investigator: Dr Steve Nicholson, University Hospitals of Leicester

ICR-CTSU Scientific Lead: Dr Emma Hall

Trial management contact: Stephanie Burnett - Trial Manager, [email protected]

ISRCTN: 78108737

Sponsor: University Hospitals Bristol NHS Foundation Trust and The Institute of Cancer Research

Funding: Cancer Research UK (CRUK/09/001)

Further information 

View Penile TPF on the National Institute for Health Research website: NIHR - Be Part Of Research

Patient friendly information on the Penile TPF trial at CancerHelp UK

Publications and presentations

Bahl A, Nicholson S, Harland S, Chester J, Pickering L, Barber J, Cruickshank C, Burnett S, Waters R, Hall E, Group obotPTM. A phase II trial of docetaxel, cisplatin, 5-fluorouracil (TPF) in locally advanced and metastatic squamous cell carcinoma (SCC) of the penis (CRUK/09/001). J. Clin. Oncol. 2012;30(Suppl 5):#326

Bahl A, Nicholson A, Harland S, Chester J, Barber J, Cruickshank C, Burnett S, Waters R, Hall E, Group ObotTTM. November, ed. A phase II trial of docetaxel, cisplatin, 5-fluorouracil (TPF) in locally advanced and metastatic squamous cell carcinoma (SCC) of the penis (CRUK/09/001). NCRI National Cancer Conference; 2011; Liverpool.

Bahl A, Nicholson S, Harland S, Chester J, Pickering L, Barber J, Cruickshank C, Burnett S, Waters R, Hall E, Group obotPTM. A phase II trial of docetaxel, cisplatin, 5-fluorouracil (TPF) in locally advanced and metastatic squamous cell carcinoma (SCC) of the penis (CRUK/09/001). Radiother. Oncol. 2011;99(Suppl 1):S507 #7110

Bahl AK, Nicholson S, Barber J, Hall E. A phase II trial of docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced and metastatic carcinoma of the penis (CRUK/09/001). J. Clin. Oncol. 2010;28(15_suppl):TPS240

Image of the Institute of Cancer Research building in Sutton
ICR joins £10million AI project to help identify individual cancer risk

22/01/25

Doctors could soon be able to better predict an individual patient’s chances of getting cancer and offer them personalised detection and prevention strategies, thanks to a new research project co-led by scientists at The Institute of Cancer Research, London.
See full story
MR linac machine - cutting edge scanner
Innovative imaging study confirms feasibility of using smaller target areas in radiotherapy for early-stage glottic cancer

21/01/25

Scientists have successfully used real-time MRI to demonstrate that swallowing causes minimal motion of the larynx, known as the voice box, in people undergoing a radiotherapy session for cancer in this part of the body.
See full story